Pharmacokinetic Interaction of Zonisamide in Rats. Effect of Other Antiepileptics on Zonisamide.

Kimura, Masahiko; Tanaka, Naomi; Kimura, Yasuhiro; Miyake, Katsushi; Kitaura, Teruaki; Fukuchi, Hiroshi

doi:10.1248/bpb1978.15.631

Cited by 18 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No significant differences in the bound fraction of each drug at two concentrations (1 and 10 Bg/ml) were observed between the control and TJ-12 groups. The protein binding rates of CBZ and CBZ-E were similar to those reported previously by Kimura et al (16) and Chang and Levy (17), respectively. The serum albumin concentrations in both control and TJ-12 groups were 3.7±O.1 g/dl, and thus were not significantly different.…”

Section: Resultssupporting

confidence: 89%

Studies on interactions between traditional herbal and western medicines. IV: Lack of pharmacokinetic interactions between Saiko-ka-ryukotsu-borei-to and carbamazepine in rats

Ohnishi

Nakasako

Okada

et al. 2001

Eur. J. Drug Metab. Pharmacokinet.

View full text Add to dashboard Cite

The possibility of pharmacokinetic interactions between Saiko-ka-ryukotsu-borei-to extract powder (TJ-12), a widely used traditional Chinese herbal (Kampo) medicine, and carbamazepine (CBZ), an important anti-epileptic drug, was examined in rats. There were no significant differences in the serum protein binding of CBZ and carbamazepine- 10,11-epoxide (CBZ-E), its active metabolite, at two concentrations (1 and 10 Bg/ml) between twogroups pretreated orally with the vehicle andTJ-12 suspension (1 g/kg/d, p.o.) for 1 week. One-week repeated pretreatment with TJ- 12 (1 g/kg/d) did not influence liver weight, contents of cytochromes P450 and b5 in hepatic microsomes or the formation rate of CBZ-E from CBZ by its microsomes, while pretreatment with phenobarbital (80 mg/kg/d, i.p.) significantly increased these parameters. Neither a single nor 1-week repeated oral pretreatment with TJ-12 (1 g/kg/d) affected the plasma concentration-time profile and any pharmacokinetic parameter of CBZ or CBZ-E after oral administration of CBZ (50 mg/kg). These results indicated that oral co-administration of TJ-12 with CBZ has no effect ofthe pharmacokinetics of CBZ or CBZ-E in rats. Concomitant treatment with TJ- 12 and CBZ appears to be pharmacokinetically safe in humans.

show abstract

Section: Resultssupporting

confidence: 89%

Studies on interactions between traditional herbal and western medicines. IV: Lack of pharmacokinetic interactions between Saiko-ka-ryukotsu-borei-to and carbamazepine in rats

Ohnishi

Nakasako

Okada

et al. 2001

Eur. J. Drug Metab. Pharmacokinet.

View full text Add to dashboard Cite

show abstract

“…Caution in those patients with personal or family history of kidney stones. Main drug interactions Clearance of zonisamide may be enhanced by combination with other AEDs [54].…”

Section: Zonisamidementioning

confidence: 99%

Progressive myoclonic epilepsies

Uthman

Reichl

2002

Curr Treat Options Neurol

View full text Add to dashboard Cite

The treatment of progressive myoclonus epilepsy (PME) remains a major therapeutic challenge in neurology. Generalized convulsive seizures are often well controlled through classic antiepileptic drugs (AEDs) like valproate and clonazepam, whereas myoclonus, the main symptom that is affecting patients most in their daily life, is usually refractory to standard AEDs. Alternative therapy concepts have been and still are investigated. Among the new drugs, zonisamide and piracetam have shown the most promising results as add-on treatments. Other therapeutic approaches, like the use of antioxidants, 5-hydroxytryptophan (5-HTP), and baclofen should also be taken into consideration for the treatment of intractable cases of PME. Nonpharmacologic treatment options such as diet and physical therapy should always be considered, because they may save costs and side effects. In some instances, the occasional use of alcohol has shown beneficial effects.

show abstract

“…ZNS may have minor inhibitory effects on the metabolism of compounds metabolized by CYP2C9 (PHT, PB, VPA), 2C19 (PHT), 2E1 and 2A6. It is unlikely that levels of these agents would be altered to a clinically significant degree [45,46]. Due to their primary renal clearance and absence of substantial hepatic metabolism, LEV and GBP are not subject to inhibition.…”

Section: Hepatic Inhibitionmentioning

confidence: 99%

Drug interactions in epilepsy care: perspective on the newer generation antiepileptic drugs

Gidal¹,

Nemergut²,

French³

2002

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

Pharmacokinetic interactions involving the antiepileptic drugs have long been considered to be an unavoidable component of epilepsy treatment. Many of the 'older' generation of antiepileptic drugs, including carbamazepine, phenytoin and phenobarbital, are recognized to cause hepatic induction of drug-metabolizing enzyme systems, such as the cytochrome P450 and UDP-gluculronyltransferase. Such interactions are not uncommonly implicated in resulting in clinically significant treatment complications. During the latter half of 1990s, a number of new antiepileptic drugs have become available to clinicians. Generally speaking, a common feature of these 'newer' generation medications are improved pharmacokinetic characteristics, including an improved drug interaction profile. The aim of this review is to summarize the data, both experimental and clinical, regarding pharmacokinetic interactions with the newer antiepileptic drugs.

show abstract

Pharmacokinetic Interaction of Zonisamide in Rats. Effect of Other Antiepileptics on Zonisamide.

Cited by 18 publications

References 19 publications

Studies on interactions between traditional herbal and western medicines. IV: Lack of pharmacokinetic interactions between Saiko-ka-ryukotsu-borei-to and carbamazepine in rats

Studies on interactions between traditional herbal and western medicines. IV: Lack of pharmacokinetic interactions between Saiko-ka-ryukotsu-borei-to and carbamazepine in rats

Progressive myoclonic epilepsies

Drug interactions in epilepsy care: perspective on the newer generation antiepileptic drugs

Contact Info

Product

Resources

About